Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals (CRNX) is a clinical-stage biopharmaceutical company pioneering oral therapies for endocrine disorders and related tumors. This news hub provides investors and industry professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Access official press releases, financial reports, and scientific updates related to CRNX's lead candidates: paltusotine for acromegaly/carcinoid syndrome and atumelnant targeting adrenal disorders. Our curated news collection enables efficient tracking of therapeutic innovations in rare diseases, partnership announcements, and market-moving events.
Content spans clinical data publications, FDA communications, executive leadership updates, and research collaborations. Bookmark this page for direct access to primary-source information about CRNX's novel small molecule therapies and their development pathways.
Radionetics Oncology announced the appointment of Umesh Gangadharmath, Ph.D., as Senior Vice President, Technical Operations. With over 16 years of radiopharmaceutical expertise, he is expected to lead the company in filing three INDs over the next two years. The company also doubled its workforce to 20 employees in a year, aiming to advance its radiotherapeutics pipeline. Radionetics focuses on peptide-targeted radiotherapeutics, projected to thrive in a market expected to reach $12.6 billion by 2027.
Crinetics Pharmaceuticals (Nasdaq: CRNX) granted non-qualified stock options for 246,600 shares to 13 new employees on September 10, 2022, under the 2021 Inducement Plan. This plan incentivizes new hires and complies with Nasdaq's Listing Rule 5635(c)(4). The options have an exercise price of $21.03 per share, reflecting the common stock's fair market value on the grant date. Shares will vest over four years, with 25% vesting annually. Crinetics focuses on developing therapeutics for rare endocrine diseases and has ongoing clinical trials for multiple drug candidates.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company will provide a corporate overview starting at 7:00 a.m. Eastern Time on September 12, 2022. Interested parties can access a webcast available on-demand.
Crinetics is focused on developing therapeutics for rare endocrine diseases, with its lead candidate Paltusotine in advanced clinical stages.
Crinetics Pharmaceuticals (CRNX) presented new data on their investigational compound, paltusotine, at the 35th Brazilian Congress of Endocrinology and Metabolism. The results show that paltusotine effectively lowers and maintains insulin-like growth factor-1 (IGF-1) levels comparable to injected somatostatin receptor ligands (SRLs) for up to 103 weeks. An impressive 88% of trial participants opted to continue treatment, with 89% preferring the oral paltusotine to injected SRLs. The drug demonstrated a safety profile similar to that of injected SRLs, indicating its potential as a long-term therapy for acromegaly.
Crinetics Pharmaceuticals (CRNX) announces that Dr. Monica R. Gadelha will present interim data from the ACROBAT Advance open label extension study at the 35th Brazilian Congress of Endocrinology and Metabolism (CBEM) on September 4, 2022. The presentation highlights paltusotine's long-term safety and maintenance of IGF-1 levels in acromegaly patients transitioning from injectable therapies. Paltusotine is an investigational oral treatment designed to selectively target somatostatin receptor type 2, aiming to improve patient compliance and outcomes.
Crinetics Pharmaceuticals (CRNX) announced that its Phase 3 PATHFNDR program for paltusotine in acromegaly and Phase 2 study for carcinoid syndrome are on schedule for top-line data in 2023. The Phase 1 data for CRN04894 confirmed pharmacologic proof-of-concept for conditions like Cushing’s disease. The company plans to initiate Phase 2 studies for CRN04777 and CRN04894 after protocol finalization with global regulators. In Q2 2022, Crinetics reported a net loss of $42.4 million on revenues of $0.4 million, while cash reserves were $408.5 million, sufficient for operations through 2024.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on August 10, 2022, the grant of non-qualified stock options for a total of 67,100 shares to nine new non-executive employees. These options, part of the 2021 Employment Inducement Incentive Award Plan, were issued to incentivize hiring as per Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $21.77 per share, matching the stock's fair market value. The options will vest over four years with 25% vesting after one year and the rest in monthly installments, contingent on continued employment.
Crinetics Pharmaceuticals (CRNX) announces Peter J. Trainer, M.D. will present findings from preclinical and Phase 1 studies of CRN04894 at the International Congress of Neuroendocrinology from August 7-10, 2022. CRN04894 is an oral ACTH antagonist targeting Cushing’s disease and congenital adrenal hyperplasia. Results show significant reductions in cortisol levels during the Phase 1 trial, affirming pharmacologic proof-of-concept. The presentation occurs on August 10, 2022, detailing the drug's impact on glucocorticoid secretion.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the grant of non-qualified stock options for 107,500 shares to six new non-executive employees on July 12, 2022. These options were awarded under the 2021 Employment Inducement Incentive Award Plan to attract new talent, complying with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $20.33 per share, reflecting the current market value. The options will vest over four years, contingent upon continued employment. Crinetics focuses on developing therapies for rare endocrine diseases, with ongoing clinical trials for key drug candidates.
On June 10, 2022, Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the grant of non-qualified stock options to purchase 138,500 shares to seven new non-executive employees. This action follows the 2021 Employment Inducement Incentive Award Plan, aimed at attracting new talent. The options have an exercise price of $18.59 per share and will vest over four years, contingent upon continued employment. This initiative aligns with Nasdaq regulations designed to incentivize new hires and support the company's growth in developing treatments for rare endocrine diseases.
